New drug combo shows promise in Hard-to-Treat cancers
NCT ID NCT06091930
First seen Oct 01, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This early-stage study tested a new drug (BI 765049) alone or with another drug (ezabenlimab) in 21 Asian adults with advanced solid tumors like lung, stomach, or liver cancer. The goal was to find a safe dose and see if the drugs could shrink tumors. Participants received infusions every 3 weeks for up to 3 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Japanese Foundation for Cancer Research
Tokyo, Koto-ku, 135-8550, Japan
-
National Cancer Center Hospital
Tokyo, Chuo-ku, 104-0045, Japan
-
National Cancer Center Hospital East
Chiba, Kashiwa, 277-8577, Japan
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Severance Hospital
Seoul, 03722, South Korea
-
Shanghai East Hospital
Shanghai, 200120, China
Conditions
Explore the condition pages connected to this study.